Clients Login

You need to upgrade your Flash Player.

Welcome to Nextcea Nextcea is dedicated to optimizing efficacious effects and to minimizing toxicity at an earlier stage in pre-clinical and clinical than is currently possible as well as to repositioning drug candidates or marketed drugs for new therapeutic uses. We integrate traditional pharmacokinetic/dynamics (PK/PD), toxicokinetics/dynamics (TK/TD), drug metabolite profiling and biomarker discovery in a single analysis. Our innovative technologies provide a new basis for decision making in drug discovery and development.       News & Events December, 2008 Elucidation of Potential Bortezomib Response Markers in Multiple Myeloma Patients more info... September 2008 Drug Metabolite Quantitation across Species more info... July 2008 Nextcea presents at Rediscovering Biomarkers conference more info... June 2008 Nextcea presents at Society of Toxicologic Pathology meeting more info... May 2008 NEXTCEA presents at Applied Pharmaceutical Toxicology meeting more info... February 2008 NEXTCEA presents at Mass Spectrometry at NJMSDG January 2008 Nextcea protein biomarker analysis article published in Pharmaceutical Research. November 2007 Nextcea offers a new user-friendly web-based PK/TK analysis tool.   more info... September 2007 Gerald Miwa joins Nextcea as President.   more info... September 2007 Nextcea drug safety article published in Tox. & Applied Pharm. Journal.) May 2007 NEXTCEA collaborates with the FDA May 2007 NEXTCEA partners with Novartis on hepatotoxicity biomarker study March 2007 NEXTCEA presents at Boston Toxicology Meeting January 2007 Phosphlipidosis biomarkers article published in Tox. & Applied Pharm. Journal